

1 **Consumption of legumes and risk of hepatobiliary diseases among humans aged**  
2 **2+ years: a scoping review**

3 Fie Langmann (MSc)<sup>1</sup>, Christopher Fisker Jensen (MSc)<sup>1</sup>, Vibeke Lie Mortensen (MSc)<sup>1</sup>, Line  
4 Rosendal (MSc)<sup>1</sup>, Niels Bock (BSc)<sup>1</sup>, Christina C. Dahm (Ph.D)<sup>1</sup>

5 1. Department of Public Health, Faculty of Health, Aarhus University, Aarhus-8000, Denmark

6

7 FL ORCID: 0000-0003-3474-9346

8 CFJ ORCID: 0000-0001-7150-2946

9 VLM ORCID: 0009-0009-1439-7233

10 LR ORCID: 0009-0003-9434-4890

11 NB ORCID: 0009-0005-7373-1589

12 CCD ORCID: 0000-0003-0481-2893

13

14 **Corresponding author**

15 Christina C. Dahm, Aarhus University, Dept. of Public Health, Bartholins Allé 2, Aarhus-8000,

16 Denmark. Email: [ccd@ph.au.dk](mailto:ccd@ph.au.dk)

17 **Abstract**

18 **Objectives:** To identify and map the literature regarding human consumption of legumes and  
19 potential relationships with hepatobiliary diseases.

20 **Background:** Consuming legumes might reduce lipid accumulation in the liver while  
21 potentially impeding the functionality of the bile duct and gallbladder. As dietary trends shift  
22 toward promoting legume consumption, exploring the positive and negative impacts on  
23 hepatobiliary health becomes crucial.

24 **Methods:** This scoping review explored the intake of dietary pulses and legumes (excluding  
25 broader dietary patterns) and their relation to hepatobiliary diseases like non-alcoholic fatty  
26 liver disease, gallstones, and gallbladder removal among individuals above the age of two  
27 years. The review included textbooks, expert opinions, and searches in four databases  
28 (PubMed, CINAHL Complete, Embase, and Web of Science). Two reviewers extracted data  
29 independently from each article. The synthesis of results was presented narratively by  
30 hepatobiliary outcomes. Unpublished studies and grey literature sources were sought out.

31 **Results:** From 19,881 records retrieved, 29 were included - 17 on non-alcoholic fatty liver  
32 disease and 12 on gallbladder diseases. Most studies were observational, but a few were  
33 narrative reviews. Some studies found a protective association between legume consumption  
34 and non-alcoholic liver disease, while others found no association. Overall, there was no clear  
35 association between legume consumption and gallbladder diseases. The studies varied in  
36 methodological quality, and confidence in the findings was low.

37 **Conclusion:** The association between legume consumption and non-alcoholic fatty liver  
38 disease was inverse or non-significant. The association between legume consumption and  
39 gallbladder disease was inconclusive. Further research is needed to draw firmer conclusions.

40 **Keywords:** Dietary pulses; Gallstone; Hepatobiliary health; Legumes; Non-alcoholic fatty  
41 liver disease

## 42 **Introduction**

43 Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, anticipated to affect  
44 around 25% of adults worldwide by 2026.<sup>1</sup> It arises from excessive fat accumulation in the  
45 liver, unrelated to notable alcohol consumption, parenteral nutrition, or medication use.<sup>2</sup> The  
46 disease encompasses non-alcoholic fatty liver (NAFL) characterized by  $\geq 5\%$  hepatic fat  
47 without apparent damage, and non-alcoholic steatohepatitis (NASH) characterized by  $\geq 5\%$   
48 hepatic fat with inflammation, with or without fibrosis.<sup>2</sup> Diagnosis with NAFLD is strongly  
49 associated with metabolic syndrome (MetS) and elevated risk of developing liver cancer  
50 compared to those without the condition.<sup>2,3</sup> No approved drug therapy exists for NAFLD, and  
51 lifestyle modifications, notably dietary changes, form primary clinical recommendations. Diets  
52 emphasizing plant-based protein sources and high dietary fiber contents are recommended.<sup>2</sup>

53 Compared to meats, legumes offer rich protein content, low saturated fat, energy density,  
54 and abundant dietary fiber, all crucial components for a healthy and balanced diet.<sup>4-6</sup> Diets  
55 enriched with legumes have further been linked to overall better diet quality and health  
56 outcomes.<sup>7</sup> Pulses (or grain legumes) are a subtype of legumes referring to crops harvested for  
57 dry grain such as lentils, chickpeas, and beans, but not fresh legumes like green beans. The  
58 term *legumes* is often used as an umbrella term for both pulses and fresh legumes.<sup>4</sup> Legumes  
59 constitute fundamental elements of various plant-based diets, providing health advantages and  
60 reducing the risk of lifestyle-related diseases compared to Western diets high in red meats, fats,  
61 and sugars.<sup>8-10</sup>

62 Prior research has shown an advantageous impact on NAFLD of dietary patterns integrating  
63 legumes, such as the Mediterranean and vegetarian diets. These benefits are often associated  
64 with the abundant presence of bioactive compounds like polyphenols and antioxidants, and the  
65 high fiber content of legumes.<sup>11,12</sup> Although legumes boast substantial amounts of bioactive  
66 components and fibers,<sup>13</sup> these bioactive components are also present in various other food

67 groups. There is a gap in understanding the comprehensive impact of whole grain legume  
68 consumption or processed legumes used in food products like plant-based meat alternatives.

69 Elevated legume intake has been linked to inhibited digestion of fats and carbohydrates,<sup>14,15</sup>  
70 which might mitigate excessive fat accumulation in hepatocytes.<sup>16,17</sup> Consequently, a lower  
71 risk of NAFLD could ensue with increased legume consumption. While human and animal  
72 studies have demonstrated the hepatobiliary benefits of plant-based diets,<sup>12,18</sup> research on  
73 legumes in isolation is scarce, rendering the evidence indirect and restricted. The pathways of  
74 NAFLD involve the bile duct and gallbladder function, where excess lipid fractions are  
75 excreted through the gallbladder.<sup>19</sup> Polyphenols, peptides, and other leguminous compounds  
76 have been associated with increased cholesterol synthesis and biliary cholesterol secretion.  
77<sup>14,15,20</sup> This may result in cholesterol saturation within the bile, potentially raising the likelihood  
78 of gallstone development,<sup>15,20,21</sup> and complications like gallbladder inflammation.<sup>22,23</sup>  
79 Following symptom onset, the annual risk of gallbladder removal is 1-2%.<sup>24</sup> Greater legume  
80 consumption might therefore correlate with a higher risk of gallstones, through the pathways  
81 that concurrently minimize the risk of NAFLD.<sup>19,20,25</sup>

82 With greater emphasis on reducing the environmental impact of Western diets through  
83 consumption of legumes,<sup>5</sup> a comprehensive investigation of potential adverse and beneficial  
84 effects is important. This scoping review therefore aimed to examine the breadth of literature  
85 about the consumption of legumes and dietary pulses, whether as whole grains or components  
86 within foods such as plant-based meat alternatives, in relation to NAFLD, gallstone, and  
87 gallstone-related diseases. This review focused on legume crops usually consumed as protein  
88 sources instead of meats, such as pulses, while excluding peanuts and legume crops used for  
89 sowing forage, such as clovers.<sup>4</sup> It targets individuals aged 2+ years, omitting young children  
90 recommended to breastfeed for at least 2 years,<sup>26</sup> without prior hepatobiliary conditions or  
91 limitations affecting nutrient digestion or absorption, across diverse geographical regions.

92 While previous research has delved into legume components, such as polyphenols or  
93 antioxidants, this scoping review explores the implications of consuming legumes beyond  
94 clinical contexts.

95 A preliminary search of PROSPERO, the Cochrane Database of Systematic Reviews, and  
96 *JBI Evidence Synthesis* was conducted. No current or in-progress scoping reviews or  
97 systematic reviews on the topic were identified.

## 98 **Review questions**

99 What research has been reported on whole grain legumes or products based on whole grain  
100 legumes and hepatobiliary disease in humans without previous hepatobiliary disease?

101 What evidence of the association between legume consumption and hepatobiliary diseases  
102 has been reported for children, the general adult population, adults with cancers, and adults  
103 with cardiovascular diseases?

104 What hepatobiliary mechanisms is the consumption of whole grain legumes considered to  
105 affect?

## 106 **Inclusion criteria**

### 107 *Participants*

108 This review encompassed studies involving individuals aged 2 years or older with no prior  
109 diagnosis of NAFLD, NASH, metabolic dysfunction-associated fatty liver disease (MAFLD),  
110 metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic  
111 dysfunction-associated steatohepatitis (MASH), gallstone (cholelithiasis), or gallbladder  
112 inflammation (cholecystitis or biliary cholangitis). The review protocol outlined that literature  
113 involving individuals who had their gallbladder removed (cholecystectomy) were not eligible  
114 for inclusion.<sup>27</sup> Cholecystectomy is, however, a common treatment and proxy for gallstones,  
115<sup>28,29</sup> and studies investigating this outcome were therefore included in the literature search.

116 Literature involving individuals who underwent partial or full surgical removal of the liver or  
117 gallbladder before entry to the study was not considered. Additionally, studies involving  
118 individuals with gastrointestinal conditions impeding digestion or nutrient absorption, such as  
119 ileostomy, colostomy, Crohn’s Disease, etc., were excluded. The review aimed to  
120 comprehensively map and describe the literature irrespective of sex. Articles focusing on  
121 animal studies were not included.

## 122 *Concept*

123 This review focused on studies examining the consumption of whole-grain legumes or  
124 products derived from whole-grain legumes, such as meat-substitute products, and their  
125 association with non-cancerous hepatobiliary diseases.

126 Legumes were defined culinarily, encompassing peas, lentils, and beans (excluding coffee  
127 and cacao beans). Fatty legumes like peanuts were not included. Studies of specific legume  
128 components (e.g., specific antioxidants, fibers, or peptides) were not within the scope of this  
129 review. Additionally, literature about *Leguminosae* or *Fabaceae* not consumed as whole grains  
130 (e.g., stems, leaves, or flowers) was not included. Materials exploring legumes within enteral  
131 or parenteral nutrition contexts were beyond the scope of this review. The outcomes of the  
132 included literature were NAFLD, NASH, MAFLD, MASLD, MASH, gallstones, gallbladder  
133 inflammation, bile duct obstruction, and gallbladder removal. In instances where the  
134 hepatobiliary condition was present at the study baseline, only investigations of NAFLD  
135 progression to NASH or case-control studies retrospectively assessing legume consumption as  
136 an exposure were eligible. In 2023, the European, American, and Latin American Associations  
137 for the Study of the Liver, announced the change of NAFLD to MASLD and NASH to MASH.  
138 <sup>30</sup> The change was made to avoid stigmatization of affected individuals and to classify the  
139 disease on the presence of specific characteristics rather than the non-presence of alcohol. <sup>30,31</sup>  
140 This change in nomenclature was accepted after the review process started and thus

141 incorporated into the literature search of this review.

#### 142 *Context*

143 Legumes and dietary pulses are consumed across various populations, cultures, and settings,  
144 serving as a dietary staple in many developing countries. As such, the review context  
145 encompassed this diverse array of settings, also including trial settings, where an intervention  
146 was evaluated. To ensure a comprehensive mapping of available evidence, restrictions based  
147 on country or date were not imposed. Articles published in Danish, Swedish, Norwegian, and  
148 English were considered for inclusion. Of the four languages, the literature search exclusively  
149 identified articles composed in English. The literature search included all literature up until  
150 June 30<sup>th</sup>, 2023.

#### 151 *Types of sources*

152 This scoping review considered all types of quantitative and qualitative study designs and  
153 reviews for inclusion. Quantitative studies, whether randomized or non-randomized controlled  
154 trials or observational, were included. Eligible qualitative studies included phenomenology,  
155 grounded theory, ethnography, and thematic analysis. Literature without evidence level that  
156 met the inclusion criteria, along with text and opinion papers, was also considered for the  
157 scoping review. Any peer-reviewed or expert publications of consensus guidelines were  
158 eligible for inclusion.

#### 159 **Methods**

160 This scoping review was conducted in line with the Preferred Reporting Items for Systematic  
161 Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR)<sup>32</sup> following an *a*  
162 *priori* protocol.<sup>27</sup>

163 *Search strategy*

164 A 3-step search strategy was performed to locate both published and unpublished literature. In  
165 step 1, an initial limited search of PubMed (National Center for Biotechnology Information,  
166 MD USA) was undertaken on February 17<sup>th</sup>, 2023. The text words contained in the titles and  
167 abstracts of relevant articles, and the index terms used to describe the articles were used to  
168 develop a full search strategy. In step 2, the full search strategy, including all identified  
169 keywords and index terms was adapted for each information source and undertaken on July  
170 24<sup>th</sup>, 2023. Fatty liver diseases have several different clinical and histological characteristics  
171 and varying nomenclature including NAFLD, MAFLD, and MASLD, which has changed over  
172 time.<sup>30,31</sup> Being observant of the recent change in nomenclature for NAFLD,<sup>33,34</sup> the literature  
173 search was also conducted for MASLD, MAFLD, and MASH until June 30<sup>th</sup>, 2023. The full  
174 search strategies are provided in Appendix I and II. In step 3, the reference lists of articles  
175 selected for full-text review were screened for additional papers. No relevant literature on  
176 MAFLD, MASLD, or MASH was found, and this review will use the terms NAFLD and  
177 NASH throughout the text. All databases were searched from the date of inception until June  
178 30<sup>th</sup>, 2023, apart from sources of unpublished and grey literature, which were narrowed to only  
179 include literature published in the year preceding June 30<sup>th</sup>, 2023. This decision was made to  
180 prevent excessive screening time.

181 The databases searched included PubMed (National Center for Biotechnology Information,  
182 MD USA), Embase (Elsevier B.V., Amsterdam, Netherlands), CINAHL Complete (EBSCO  
183 Information Services, MA, USA), and Web of Science (Clarivate Analytics, PA, USA).  
184 Sources of unpublished studies and gray literature searched included Google Scholar (Google  
185 Inc., CA, USA) and ProQuest (ProQuest LLC, MI, USA). OpenGrey was discontinued in 2020  
186 and therefore not included as a literature source.<sup>35</sup>



187 *Study selection*

188 All identified records were collated in Covidence (Veritas Health Innovation Ltd, Melbourne,  
189 Australia), and duplicates were removed. Following a pilot test, titles and abstracts were  
190 screened by two independent reviewers for assessment against the inclusion and exclusion  
191 criteria for the review. Articles not meeting the criteria for inclusion were excluded, and  
192 potentially relevant papers were retrieved in full and assessed in detail against the inclusion  
193 criteria by two independent reviewers (FL and VLM, LR, CFJ, or NB). Full-text studies that  
194 did not meet the inclusion criteria were excluded, and reasons for their exclusion are provided  
195 in Appendix III. Disagreements between reviewers at any stage of the selection process were  
196 resolved through discussion or with a third reviewer (CCD).

197 *Data extraction*

198 Data were extracted into a data extraction table based on the draft form presented in the  
199 protocol.<sup>27</sup> Data extraction from the included literature was carried out by one author (FL) and  
200 reviewed by a second author (VLM, CFJ, LR, NB, or CCD). The data extraction table was  
201 piloted by two reviewers (FL and CCD) and minimally modified to include information on the  
202 author, aim, and study type in the same column. Extracted data included specific details about  
203 the population, concept, context, statistical methods, confounding factors, and key findings. An  
204 outline of the final data extraction table used for data extraction can be found in Appendix IV.  
205 Any disagreements between reviewers were resolved through discussion or with a third  
206 reviewer.

207 *Data analysis and presentation*

208 Summaries of all included studies are presented in tables according to hepatobiliary disease  
209 type (NAFLD or gallbladder diseases [GBD]) and further presented by i) study design for  
210 evidence-level articles, or ii) article type for non-evidence articles. Results from evidence-level  
211 articles are presented in tables developed from the draft results table presented in the protocol

212 for this review<sup>27</sup> and summarized in narrative reviews together with data from non-evidence  
213 articles to answer the review questions. All evidence-level articles were subject to a quality  
214 assessment to ensure that any conclusions, and implications for research or practice,  
215 considered not only results but also the methodological soundness of the included studies. Two  
216 independent reviewers (FL and VLM, CFJ, LR, or NB) assessed methodological quality  
217 following assessment templates (Appendix V) for the specific study design.

218 Cohort and case-control studies were assessed with the Scottish Intercollegiate Guidelines  
219 Network (SIGN) checklists for observational studies.<sup>36</sup> SIGN includes 14 statements for  
220 cohort studies evaluating the internal validity followed by an overall evaluation with three  
221 statements and a note section. Case-control studies were assessed based on 11 statements  
222 evaluating the internal validity followed by an overall evaluation with three statements and a  
223 note section. For both cohort and case-control studies, each statement was answered yes, no, or  
224 unknown and the overall evaluation of minimized bias was rated as high, acceptable, or  
225 unacceptable based on the internal validity and consensus reached between the assessors. The  
226 SIGN checklist for case-control studies included an unclear description for assessing  
227 statement, 1.9: “Exposure status is measured in a standard, valid, and reliable way.” The  
228 description focused solely on the measurement of outcomes rather than exposure status.<sup>36</sup>  
229 SIGN was contacted to clarify the statement and sent a response to the authors on March 1<sup>st</sup>,  
230 2024. Due to the late response, the authors reached a consensus in November 2023 that the  
231 statement should include exposure and outcome measurement assessments, as both are  
232 essential for the methodological quality of case-control studies. Statement 1.9 was thus  
233 amended to: “Exposure and outcome status are measured in standard, valid, and reliable ways”.  
234 With the assessment description: “The study needs to outline the exposure and outcome  
235 measures employed, explicitly. It should detail how exposure levels were determined, ensuring  
236 a clear understanding of whether participants were exposed to the investigated factor and to

237 what extent. Additionally, if the outcomes involve any subjective elements, the study should  
238 offer evidence validating the reliability of these measures before their application. Clear,  
239 comprehensive descriptions of reliable measures enhance the study's credibility. Studies  
240 omitting outcome measures or heavily rely on secondary outcomes may warrant rejection”.

241 Cross-sectional studies were assessed using the Appraisal of Cross-sectional Studies  
242 (AXIS) tool comprising 18 statements evaluating internal validity. Two statements were used  
243 to evaluate ethics and conflicts of interest.<sup>37</sup> The reviewers added a note section to the  
244 assessment tool. Each statement was answered yes, no, or unknown and the overall  
245 methodological quality was evaluated as high, moderate, low, or very low based on consensus  
246 reached between reviewers.

247 Systematic reviews and meta-analyses were assessed with A MeaSurement Tool to Assess  
248 systematic Reviews (AMSTAR-2) based on 16 statements that answered yes, no, or partly yes.  
249<sup>38</sup> The overall confidence in results was evaluated as high, moderate, low, or critically low  
250 based on consensus reached between reviewers.

## 251 **Results**

### 252 *Article inclusion*

253 The literature search of published literature yielded 19,881 records. After the removal of  
254 duplicates, 16,498 titles and abstracts were screened, and 57 full-text records were assessed for  
255 eligibility with 33 not meeting the inclusion criteria (Appendix III). Five records were included  
256 through other methods including hand searches of reference lists of articles assessed for  
257 full-text eligibility, and from the search of unpublished and grey literature. Twentynine records  
258 were included in the review (Figure 1).

### 259 *Characteristics of included studies*

260 Of the 29 articles included, two presented data from the same study,<sup>39,40</sup> the narrative reviews  
261 presented data from four primary studies<sup>25,41-43</sup> and one systematic review,<sup>3</sup> which was also

262 included in the scoping review. The systematic review presented data from four primary  
263 studies.<sup>42-45</sup>

264 The characteristics of the included studies are summarized in Table 1 and elaborated in  
265 Appendix VI. There were 17 articles focusing on NAFLD (1 cohort study,<sup>40</sup> 5 case-control  
266 studies,<sup>43,46-49</sup> 9 cross-sectional studies,<sup>39,42,44,45,50-54</sup> 1 systematic review,<sup>3</sup> 1 narrative  
267 review<sup>55</sup>). Most were from Asian countries (5 China, 1 Korea, 1 Taiwan 1 Japan) or South  
268 European countries (4 Italy, 1 Spain) with the remaining from Western Europe (1 Germany, 1  
269 UK) and the Middle East (2 Iran). Twelve articles focused on GBD (2 cohort studies,<sup>41,56</sup> 5  
270 case-control studies,<sup>25,57-60</sup> 2 cross-sectional studies,<sup>61,62</sup> 3 narrative reviews<sup>21,63,64</sup>). The  
271 studies were geographically spread across Asia (2 India, 1 Pakistan), South Europe (1 France, 1  
272 Greece, 1 Italy), North America (3 USA), Western Europe (1 The Netherlands), Middle East (1  
273 Saudi Arabia) and one of unknown origin.<sup>64</sup>

#### 274 *Review findings*

275 The literature search did not return any studies on children or individuals with cancers. As only  
276 two studies investigated NAFLD among individuals with CVD, the results are presented  
277 together with the studies investigating NAFLD among healthy individuals. There were no  
278 GBD studies on individuals with CVD. Table 2 and 3 presents results and quality assessment  
279 ratings for studies focusing on NAFLD and GBD, respectively.

#### 280 *Legumes and risk of NAFLD*

281 One study investigated the longitudinal association of replacing animal-based proteins with  
282 legumes in a large sample of individuals from Tianjin Chronic Low-grade Systemic  
283 Inflammation and Health Cohort (TCLSIH) and Guangzhou Nutrition and Health Study  
284 (GNHS), two large national cohorts in China.<sup>40</sup> Substituting poultry for legumes was  
285 associated with a lower HR of NAFLD (HR: 0.35, 95% CI: 0.18; 0.69, and HR: 0.92, 95% CI:

286 0.86, 1.00 in GNHS and TCLSIH respectively).<sup>40</sup> Substituting one serving of processed meat  
287 with one serving of legumes was associated with a lower risk of NAFLD in TCLSIH (HR:  
288 0.86, 95% CI: 0.74; 1.00), while the GNHS did not differentiate between red and processed  
289 meat and found a higher risk of NAFLD when replacing one serving of red meat with one  
290 serving of legumes (1.16, 95% CI: 0.99; 1.37).<sup>40</sup> The methodological quality was evaluated as  
291 high (Appendix V).

292 Five case-control studies found heterogeneous results. Bahrami et al.<sup>43</sup> investigated the  
293 association between increasing legume consumption by 1 serving/week and NAFLD among  
294 196 Iranian cases and 803 controls. The association for beans, lentils, and total legumes were  
295 each assessed separately and showed a significantly lower odds ratio (OR) for NAFLD when  
296 increasing the consumption with 1 serving/week across any legume category. Giraldi et al.<sup>46</sup>  
297 investigated the association between the Mediterranean dietary pattern and NAFLD among  
298 371 Italian individuals with NAFLD and 444 controls. In sub-analyses, the authors found that  
299 the highest compared to lowest legume consumption was associated with lower OR for  
300 NAFLD (OR: 0.62, 95%CI: 0.38; 0.99).<sup>46</sup> Han et al.<sup>47</sup> assessed the association between daily  
301 bean intake and NAFLD in 169 cases and 179 controls. The odds for developing NAFLD did  
302 not differ between the lowest and highest tertile of bean intake (OR for men: 1.50, 95% CI:  
303 0.59; 3.84, OR for women: 1.13, 95% CI: 0.44; 2.89).<sup>47</sup> Hao et al.<sup>48</sup> investigated the  
304 association between the consumption frequency of beans and NAFLD in individuals with  
305 different genotypes for methylenetetrahydrofolate reductase (MTHFR). They found lower OR  
306 for NAFLD with higher consumption frequency of beans. However, the study only included  
307 information on weekly frequency (OR: 0.701, 95% CI: 0.576; 0.853).<sup>48</sup> There was some  
308 evidence of differing associations by MTHFR-genotype (OR for CC genotype: 0.807, 95% CI:  
309 0.541; 1.204, OR for CT+TT genotype: 0.670, 95% CI: 0.535; 0.839).<sup>48</sup> Tutunchi et al.<sup>49</sup> found  
310 little evidence of an association between legume consumption and NAFLD (OR: 0.74, 95% CI:

311 0.61; 1.67) among 105 Iranian cases and 105 controls. The quality assessment of the  
312 case-control studies ranged from high to poor (Appendix V).

313 The nine cross-sectional studies investigating the association between legume consumption  
314 and NAFLD generally found inverse associations, often not statistically significant. Baratta et  
315 al.<sup>44</sup> found little evidence of an association between higher legume consumption and NAFLD  
316 among 584 Italian participants (OR: 0.675, 95% CI: 0.370; 1.230). Bullón-Vela et al.<sup>50</sup>  
317 included 328 Spanish individuals with MetS and found that the highest compared to lowest  
318 tertile of legume consumption (g/day) was associated with a lower relative risk ratio (RRR) for  
319 high liver fat content (RRR: 0.48, 95%CI: 0.24; 0.97). Chan et al.<sup>45</sup> investigated the association  
320 between soy product consumption and NAFLD among 797 Chinese individuals and found  
321 little evidence of an association (OR: 0.86, 95% CI: 0.52; 1.42). Chiu et al.<sup>42</sup> investigated  
322 substituting one serving of meat with one serving of soy in 3279 Taiwanese individuals and  
323 found no association with NAFLD (OR: 0.95, 0.88; 1.02). Mirizzi et al.<sup>51</sup> included baseline  
324 information on 136 individuals from a 6-arm RCT study and observed evidence of an  
325 association between chickpea consumption and NAFLD severity (OR: 0.57, 95%CI: 0.34;  
326 0.97), but not for soy milk and dried peas. Vijay et al.<sup>52</sup> observed some evidence of an  
327 association between consumption of dried pulses and legumes and NAFLD among Indian  
328 individuals (OR: 0.43, 95% CI: 0.21; 0.61). Watzinger et al.<sup>53</sup> found little evidence of an  
329 association comparing the lowest and highest quintiles of legume consumption and NAFLD  
330 among 136 German individuals recruited for the HELENA trial (OR: 1.78, 95% CI: 0.57;  
331 5.55). In a Japanese sample of 431 participants, Yabe et al.<sup>54</sup> observed little evidence of an  
332 association between consumption of soybeans or soybean products  $\geq 4$  times/week compared  
333 to once weekly and NAFLD (OR 0.57, 95% CI: 0.27;1.19). Zhang et al.<sup>39</sup> stratified their  
334 analyses according to sex, age, and BMI, and found some evidence of an association between  
335 soy food intake  $\geq 4$  times/week compared to  $<1$  time/week and NAFLD for age  $< 50$  years (OR:

336 0.70, 95% CI: 0.59; 0.84), BMI  $\geq$  24 kg/m<sup>2</sup> (OR: 0.76, 95% CI: 0.65; 0.89), and men (OR:  
337 0.73, 95% CI: 0.61; 0.87). The cross-sectional studies were evaluated to be of varying  
338 methodological quality, ranging from poor to high, primarily due to missing information on  
339 selection procedures. Some studies validated their measurement methods, while others did not,  
340 but considerations regarding study design or adjustment levels to account for confounding  
341 factors were often poorly described or inadequately implemented (Appendix V).

342 Three cross-sectional and one case-control study were summarized in a systematic review  
343 investigating various food groups and their relation to NAFLD.<sup>3</sup> These studies were also  
344 included in this current scoping review.<sup>42-45</sup> The pooled analysis of the cross-sectional studies  
345 observed little evidence of an association between legume consumption and NAFLD (OR:  
346 0.943, 95% CI: 0.877; 1.014).<sup>3</sup> The confidence in the results from the review was evaluated as  
347 moderate (Appendix V).

348 One narrative review proposed that the mechanisms underlying the potential association  
349 between legumes and NAFLD were due to alterations in glucose and lipid metabolism.<sup>55</sup> This  
350 was based on animal studies indicating that a globulin, beta-conglycinin from soy,  
351 downregulates the expression of PPAR $\gamma$ -2 in animal models, which has been associated with  
352 obesity and storage of lipids in the liver.<sup>65</sup> The review presented findings from Bahrami et al.<sup>43</sup>  
353 and an RCT of 42 premenopausal women with central obesity who experienced decreased  
354 levels of the liver health biomarkers aspartate aminotransferase (AST) and alanine  
355 aminotransferase (ALT) when consuming a hypocaloric diet with legumes for six weeks  
356 compared to a hypocaloric diet without legumes.<sup>55</sup>

### 357 *Legumes and risk of GBD*

358 Barré et al.<sup>56</sup> investigated the risk of gallbladder removal in the French E3N cohort and found  
359 evidence of lower risk (HR: 0.73, 95% CI: 0.65; 0.82) among those consuming more than 27.8  
360 g/day compared to 0 g/day. Another prospective cohort using data from the Nurses' Health

361 Study across 1,060,033 person-years did not find clear evidence of an association between  
362 legumes and gallbladder removal (HR: 1.02, 95%CI: 0.94; 1.12).<sup>41</sup> The studies were evaluated  
363 as having high and moderate study quality, respectively (Appendix V).

364 Five case-control studies investigated the association between legume consumption and  
365 GBD and observed mixed directions of associations. Jayanthi et al.<sup>57</sup> investigated the odds of  
366 gallstone formation based on the consumption frequency of tamarind bean paste among 346  
367 cases and 346 controls in India. They observed evidence of a positive association between  
368 consuming bean paste  $\geq 3$  times weekly compared to  $< 3$  times weekly (OR: 1.79, 95% CI: 1.09;  
369 2.93). Parveen et al.<sup>59</sup> included 100 cases and 100 controls from Pakistan and also observed a  
370 positive association between consuming peas once weekly and the development of gallstones  
371 (OR: 3.37, 95% CI: 1.20; 9.60). Pastides et al.<sup>60</sup> did not observe evidence of an association in  
372 Greek women between legume consumption and gallstones in a linear trend analysis  
373 (chi-squared: 2.97,  $p=0.085$ ) among 84 cases and 171 controls, while Rasheed et al.<sup>58</sup> found a  
374 significantly higher intake of legumes among 157 gallstone cases compared to 175 healthy  
375 controls (consumption among cases 43.3 %, controls 33.3 %,  $p<0.05$ ) in females from Saudi  
376 Arabia. Thijs et al.<sup>25</sup> observed an inverse association between legume consumption frequency  
377 and gallstones in a case-control study of 204 cases and 615 controls from the Netherlands.  
378 Consuming legumes eight or more times monthly compared to less than once monthly was  
379 associated with significantly lower odds of gallstones (OR: 0.4, 95%CI: 0.23; 0.87).<sup>25</sup> The  
380 large variation in results may be caused by the methodological quality, which was rated as poor  
381 for all studies (Appendix V).

382 Two cross-sectional studies investigated the association between legume consumption and  
383 GBD. Tseng et al.<sup>61</sup> investigated the prevalence OR (POR) of GBD among 4641 Mexican  
384 Americans from NHANES III by comparing the consumption frequency of legumes and  
385 observed only weak evidence of an association among those consuming beans every day



386 compared to less than once weekly (POR: 0.59, 95% CI: 0.24; 1.44). However, when  
387 stratifying the sample on gender and only including individuals who were unaware of having  
388 prevalent gallstones, women consuming legumes daily compared to less than once weekly had  
389 a higher POR for gallstones (POR: 1.58 (1.02; 2.46). Unisa et al.<sup>62</sup> observed evidence of a  
390 positive association between chickpea consumption and gallstone prevalence among men (OR:  
391 2.55, 95% CI: 1.56; 4.15) but only weak evidence among women (OR: 1.35, 95% CI: 0.98;  
392 1.86) in a sample of 6548 Indian participants. The methodology of the studies was rated as low  
393 and very low, respectively (Appendix V).

394 Three narrative reviews<sup>21,63,64</sup> suggested that consuming legumes may be linked to a higher  
395 occurrence of gallstones since the prevalence of gallstones is very high among populations who  
396 consume legumes such as beans as a dietary staple. The prevalence of gallstone and GBD can  
397 partly be attributed to cholesterol supersaturation of the bile caused by high legume intakes.  
398<sup>63,64</sup> Being overweight and obese significantly increases the risk of gallstone formation and  
399 75% of all gallstones in Western countries are related to metabolic abnormalities such as type 2  
400 diabetes, MetS, and NAFLD.<sup>63</sup> Gaby et al.<sup>21</sup> further described that food allergies may play a  
401 role in inhibiting gallbladder emptying and thus modify the association between certain foods  
402 and GBD, which may pose an additional risk in individuals with food allergies.

## 403 **Discussion**

404 The literature on the association between legume consumption and NAFLD indicated some  
405 evidence of a lower risk of NAFLD with high legume consumption. Ten articles reported an  
406 inverse association, while seven articles reported no clear association. However, the  
407 methodological quality of the included studies was generally low or moderate and high for only  
408 three. This warrants further research with more transparent reporting in order to draw  
409 conclusions on the association between legumes and NAFLD risk with greater certainty.

410 For GBD, the literature was inconclusive of the direction of associations. Two articles found  
411 an inverse association, two found no association, and five found a positive association between  
412 legume consumption and GBD. The methodological quality of the included studies was  
413 generally low, with only one study evaluated as of high quality. The discrepant results and  
414 generally poor study quality contribute to the lack of clear evidence of an association between  
415 legume consumption and GBD.

416 The large variation in results may be caused by bias introduced by poor methodological  
417 quality of the studies lacking information on case ascertainment, validation of diet information,  
418 and small sample sizes, but may also result from the inclusion of populations with different  
419 food cultures. Previous research has indicated that plant-based meat alternatives are  
420 understudied in relation to health.<sup>66,67</sup> No studies in this review investigated the association  
421 between plant-based meat alternatives and NAFLD or GBD, and this association was not  
422 evaluated.

### 423 **Dietary assessment**

424 Short-term dietary assessments may not be fit for estimating habitual dietary intake, despite  
425 offering detailed information.<sup>68,69</sup> Particularly for periodically consumed foods, a food  
426 frequency questionnaire (FFQ) may be a more efficient for capturing habitual dietary intakes.  
427<sup>69,70</sup> However, habitual diet can be equally well estimated when using three or more short-term  
428 dietary assessments.<sup>71</sup> Measurement errors are not uncommon and the diet assessment tool  
429 should therefore be validated as an appropriate tool to measure dietary exposure in the  
430 population of interest.<sup>69,70,72</sup> The validity of an FFQ is often evaluated against another diet  
431 assessment method with 24-hour recalls or food diaries being most common due to their high  
432 detail level for quantification of intakes.<sup>68-71</sup> Biomarker validation has also emerged in recent  
433 years to assess nutrient intakes.<sup>70,72,73</sup> The strength in validating different diet assessment

434 methods against each other, and potentially also against biomarkers, is the differences in  
435 potential measurement errors between assessment methods.<sup>69-71,73</sup>

#### 436 *Studies on NAFLD*

437 Most studies on NAFLD used FFQs to assess dietary intakes.<sup>39,40,42-46,48,50-54</sup> Several studies  
438 evaluated reproducibility between two FFQs filled in at least one year apart. Furthermore, the  
439 FFQs were most often validated against other dietary assessment methods or biomarker  
440 assessments of nutrient intake. Some studies used validated, but poorly described or designed,  
441 FFQs while others again did not use validated methods to assess dietary intakes.

442 The prospective follow-up study and one case-control study used validated FFQs to assess  
443 dietary intakes,<sup>40,43</sup> while two case-control studies used non-validated FFQs.<sup>46,48</sup> Two  
444 case-control studies used short-term dietary assessments without validation,<sup>47,49</sup> offering only  
445 snapshots of dietary intakes potentially inadequate for investigating long-term diet-disease  
446 associations.<sup>68</sup> There was no clear pattern between validated dietary assessments and the  
447 association between legume consumption and NAFLD among the retrospective or prospective  
448 studies. The two studies with validated FFQs<sup>40,43</sup> found differing results like the studies using  
449 non-validated FFQs, which also reported inverse or no association.<sup>46,48</sup> The studies using  
450 short-term diet assessment found no association.<sup>47,49</sup> Six cross-sectional studies used validated  
451 FFQs,<sup>39,42,44,50,51,53</sup> and three used non-validated FFQs.<sup>45,52,54</sup> The magnitude and direction of  
452 associations reported in studies with validated FFQs were not uniform and differing results  
453 were found. Those employing non-validated FFQs all found no association between legume  
454 consumption and NAFLD. This could indicate that the non-validated FFQs employed in the  
455 cross-sectional settings may not adequately estimate habitual dietary intake and thus cause  
456 non-differential misclassification biasing the estimate towards the null.

457 There was no clear pattern between the validation of dietary assessment and the association  
458 between legume consumption and NAFLD. The direction and magnitude of associations

459 varied across study designs and the validity of diet assessments. There was some indication that  
460 using non-validated short-term dietary assessments and cross-sectional studies using  
461 non-validated FFQs resulted in non-significant associations. The lack of clear and validated  
462 diet assessments raises doubts on their accuracy, raising concerns that they may not accurately  
463 reflect habitual legume intake or the true association between legume consumption and  
464 NAFLD. Furthermore, retrospective case-control studies and cross-sectional studies can be  
465 particularly susceptible to differential misclassification as exposure and outcome assessments  
466 may affect each other.<sup>74</sup> Despite some studies not validating their diet assessment methods,  
467 many studies using valid FFQs found non-significant associations between legume  
468 consumption and NAFLD.<sup>40,42,44,51,53</sup> The studies employing non-validated exposure  
469 assessments did, however, mostly find inverse associations between legume consumption and  
470 NAFLD, which suggests that methodological differences in exposure assessment may in part  
471 drive the divergent findings.

#### 472 *Studies on GBD*

473 The two prospective cohorts investigating GBD used FFQs validated against a short dietary  
474 assessment method<sup>41,56</sup> but found different magnitudes of associations indicating an inverse  
475 association or no association between legume consumption and GBD. Of the five case-control  
476 studies, four used non-validated dietary assessment methods,<sup>25,57,59,60</sup> while one failed to  
477 include information on the validation.<sup>58</sup> Two studies used questionnaires with one collecting  
478 information on diet together with other factors for GBD,<sup>58</sup> while the other did not include  
479 details on the questionnaire apart from the description of one question regarding the  
480 consumption frequency of beans and legumes over the past month.<sup>25</sup> Three studies assessed  
481 dietary intake through interviews,<sup>57,59,60</sup> of which two studies also assessed other factors  
482 related to GBD during the diet assessment interviews.<sup>59,60</sup> Despite the heightened precision in  
483 diet assessment through trained personnel conducting the interviews, the interviews as a tool

484 were not validated. This also raises concerns about the ability to assess intakes of all legume  
485 foods or quantities consumed, underscoring the necessity for a comprehensive food intake  
486 evaluation to ensure a valid measure of habitual intake. These issues could potentially explain  
487 the heterogeneity in results due to different levels of misclassification. This renders some  
488 uncertainty as to whether the estimated association reflects the true association between  
489 legume consumption and GBD. The two cross-sectional studies did not use validated dietary  
490 assessment methods or failed to describe the validation.<sup>61,62</sup> One study adapted a previously  
491 validated FFQ to its study population,<sup>61</sup> while the other study did not account for the validity of  
492 their interview-based approach.<sup>62</sup>

493 The poor validation of dietary assessment or lack thereof across the different study designs  
494 may have introduced information bias, rendering uncertainty about the estimated associations'  
495 ability to reflect the true association between legume consumption and GBD. However, the  
496 studies using valid diet assessments also found different directions and magnitudes of  
497 association, indicating that the dietary assessment validation might not be a main driver for the  
498 diverging results across studies.

#### 499 **Outcome assessment**

500 Liver biopsies are the most accurate tool for diagnosing NAFLD, but also invasive and painful.  
501 Less invasive methods includes liver imaging such as ultrasound or magnetic resonance  
502 imaging (MRI), which have been found valid for diagnosing NAFLD with high specificity and  
503 precision when images are interpreted by a gastroenterological or hepatological expert.<sup>75-78</sup>  
504 The standard criteria for the non-invasive diagnosis of NAFLD require an indication of a  
505 “bright liver pattern” with a hepatic fat content of  $\geq 5\%$  in the absence of excessive alcohol  
506 consumption.<sup>75-78</sup>

507 The most common assessment of gallstones is ultrasound examination, which has been  
508 validated to have high specificity and sensitivity for detecting gallstones when conducted by a

509 trained specialist.<sup>79</sup> Since the most common treatment of symptomatic gallstones is surgical  
510 removal, cholecystectomy, the presence of gallstones will be diagnosed directly during the  
511 surgery for most cases.<sup>79</sup>

#### 512 *Assessment of NAFLD*

513 Several of the studies used validated NAFLD assessment methods. Seven studies used the  
514 standard “bright liver pattern” criteria for diagnosing NAFLD with ultrasound or MRI imaging  
515 evaluated by one or more trained hepatologists or gastroenterologists.<sup>43-46,48,49,53,75-77</sup> Seven  
516 studies defined NAFLD based on fat deposition in the liver assessed through echogenicity or  
517 elastography conducted by experienced technicians.<sup>39,40,42,43,51,52,54,75-78</sup> One study employing  
518 ultrasound imaging did not clarify the criteria for NAFLD diagnosis,<sup>47</sup> and another used a  
519 non-imaging technique to diagnose NAFLD with the hepatic steatosis index.<sup>50</sup> This method  
520 incorporates ALT:AST ratio, BMI, diabetes status, and female sex and has been validated  
521 against liver biopsies for NAFLD diagnosis.<sup>50,80</sup> Two studies supported their imaging  
522 technique by using composite diagnosis methods incorporating levels of ALT and AST.<sup>43,54</sup>

523 All studies, except one, reported validated outcome measures to diagnose NAFLD and  
524 differences in results across studies can hardly be attributed to the outcome assessment  
525 methods.

#### 526 *Assessment of GBD*

527 The included studies in GBD used three outcome assessment methods: surgery, imaging, and  
528 self-reported outcomes. The two prospective cohorts used self-reported cholecystectomy as  
529 outcomes.<sup>41,56</sup> Both studies validated the outcome against medical records with high reliability  
530 and validity. Furthermore, self-reported cholecystectomy increases accuracy in reporting  
531 compared to self-reported gallstones, as gallstones may be non-symptomatic. Three  
532 case-control studies used validated and non-invasive imaging to diagnose gallbladder diseases,

533 <sup>25,58,60</sup> while two studies failed to clarify their diagnostic criteria. <sup>57,59</sup> This did not seem to  
534 impact the observed association between legume consumption and GBD, as the direction and  
535 magnitude varied across all studies independent of valid or non-valid outcome assessments.  
536 The two cross-sectional studies used valid outcome assessments with ultrasound imaging and  
537 expert radiologists interpreting the images. <sup>61,62</sup> As the studies found opposite directions of  
538 associations between legume consumption and GBD, the differences cannot be ascribed to the  
539 outcome assessment methods.

540 Poor description of diagnostic criteria or lack of validation raises uncertainty about  
541 diagnoses, which could potentially cause misclassification and biased estimates. Despite some  
542 studies poorly describing outcome assessment methods, there was no clear pattern between the  
543 direction and magnitude of associations between legume consumption and GBD across the  
544 validity of outcome assessments. Furthermore, most studies had ultrasound experts or senior  
545 radiologists assessing the images to diagnose GBD providing some certainty in the outcome  
546 assessments. Erroneously defined outcomes do not appear to be the major driver of the  
547 different study results.

## 548 **Adjustment strategies**

### 549 *Studies on NAFLD*

550 The association between diet and NAFLD is prone to confounding from age, sex, alcohol  
551 consumption, physical activity, obesity or overweight, and metabolic factors such as  
552 dyslipidemia, MetS, and type 2 diabetes. <sup>39,40,42,45,47,48,52,54</sup> All studies accounted for age, while  
553 three studies did not account for sex. <sup>47,48,50</sup> Several studies failed to adjust or account for  
554 important confounding factors like alcohol consumption, <sup>43,48</sup> <sup>53</sup> physical activity, <sup>44,45,48,51,52</sup> <sup>53</sup>  
555 obesity or overweight, <sup>47,48,51,54</sup> and metabolic factors. <sup>48,49,51,52,54</sup> Furthermore, seven studies  
556 did not adjust for other foods consumed, <sup>45-49,52</sup> <sup>53</sup> and only six studies accounted for SES.  
557 <sup>39,40,42,47,49,52</sup> The context in which a person lives his or her general life has in various research

558 been shown to be important in relation to diet and health. Living alone has been associated with  
559 poorer diet quality and poorer health outcomes than cohabiting with others.<sup>81,82</sup> It could be  
560 assumed individuals living alone may also be at greater risk of developing NAFLD due to  
561 poorer dietary habits and overall poorer health. Therefore, not adjusting for cohabitation might  
562 bias the estimated association between diet and NAFLD toward the null.

563 Several of the studies failed to account for important confounders of the association which  
564 may bias estimates towards and away from the null. This raises uncertainty that the estimated  
565 associations reflect the true associations between legume consumption and NAFLD due to  
566 residual confounding, which could partly explain the difference in results, with the majority  
567 being non-significant potentially due to residual confounding biasing the estimates towards the  
568 null.

#### 569 *Studies on GBD*

570 Important confounding factors related to the association between diet and GBD are age, sex,  
571 parity, hormonal drug use for women, pregnancy, physical activity, smoking, and obesity,  
572 overweight, or rapid weight loss.<sup>15,41,56,58-63</sup> Several studies failed to account for many of these  
573 confounding factors. Two studies did not mention adjustment levels, and both of these found  
574 that higher legume consumption was associated with greater risk of GBD.<sup>57,58</sup> Four studies  
575 accounted for age and sex through design or adjustments but failed to otherwise include or  
576 describe the inclusion of other important covariates.<sup>25,59,60,62</sup> Despite one of the studies trying  
577 to increase the comparability of controls and cases through different matching strategies for  
578 acute and non-acute cases,<sup>25</sup> all studies had substantial risk of residual confounding. This  
579 might potentially explain the opposite directions of associations found, with one study finding  
580 a positive association between legume consumption and GBD,<sup>62</sup> one finding an inverse  
581 association,<sup>25</sup> and two finding no association.<sup>59,60</sup> Some studies accounted for a multitude of  
582 potential confounding factors including sex, age, dietary habits, weight loss, smoking,



583 overweight or obesity, hormonal drug use for women, parity, pregnancy, etc.<sup>41,56,61</sup> Despite the  
584 various adjustment levels, important factors like physical activity, SES, and cohabitation were  
585 not included. Furthermore, the obtained results were of different direction and magnitude  
586 implying that the multiple-adjusted analyses did not obtain more uniform associations than the  
587 poorly adjusted analyses. One of the studies failed to present the results of the  
588 multivariable-adjusted analysis,<sup>61</sup> raising concerns about residual confounding and bias of the  
589 estimated association.

590 The large variation in adjustment for confounders together with differences in outcome  
591 definitions render the certainty of the estimated associations unclear due to the substantial risk  
592 of residual confounding. All studies failed to include important confounding factors such as  
593 physical activity, SES, parity, cohabitation, and rapid weight loss. The differences in  
594 adjustment levels and statistical analyses can most likely explain the diverging results across  
595 studies.

## 596 **Population differences**

597 This review encompasses a broad range of population samples with undoubtedly different food  
598 cultures. Diet is shaped by local culture and varies between ethnicities, cultural groups, and  
599 genders, and may also vary because of personal preference and food availability.<sup>83</sup>

600 Furthermore, SES and cohabitation have been shown to impact an individual's dietary habits  
601 and health.<sup>81,82,84</sup>

## 602 *Studies on NAFLD*

603 For the association between legume consumption and NAFLD there appears to be some  
604 distinction between food cultures. The Asian cuisine and food culture traditionally includes  
605 more legumes and an overall healthier diet compared to Western diets.<sup>85,86</sup> However, the  
606 studies with Asian populations<sup>39,40,42,45,47,48,52,54</sup> did not find clear associations between

607 legumes and NAFLD. Results were of somewhat diverging directions, and magnitudes  
608 indicated that the cultural meal setting, and foods consumed in combination with legumes may  
609 be important for the risk of developing NAFLD. There appear to be promising hepatobiliary  
610 health benefits for the studies including Middle Eastern and Mediterranean populations.  
611 Legumes are a staple food in many Middle Eastern countries, and both studies with Middle  
612 Eastern populations found inverse associations between legume consumption and NAFLD.  
613 <sup>43,49</sup> Furthermore, the foods typically consumed together with legumes in the Mediterranean  
614 areas such as fish, plant-based fats, and nuts may provide an optimal combination of food  
615 matrices and nutrients to lower the risk of NAFLD. All studies with Mediterranean populations  
616 found inverse associations between legume consumption and NAFLD. <sup>44,46,50,51</sup> Meanwhile,  
617 foods typically consumed in combination with legumes in Central Europe may to a greater  
618 extent include animal-based fats from butter, lard, or dairy, and coarse vegetables like kale,  
619 cabbage, and onion, which could explain the positive association between legume consumption  
620 and NAFLD in the study including a Central European population. <sup>53</sup>

### 621 *Studies on GBD*

622 The combination of foods consumed, which is highly dependent on food culture and tradition  
623 and varies across geographical locations, may significantly impact the association between  
624 legume consumption and GBD. The studies including populations with tradition of consuming  
625 pulses such as Asian <sup>57,59,62</sup> and Middle Eastern <sup>58</sup> populations indicated that legume  
626 consumption was associated with a greater risk of GBD. However, one study included a  
627 population of Mexican Americans, <sup>61</sup> who also have tradition of consuming beans, <sup>87</sup> but did not  
628 find any association between legume consumption and GBD. This study sampled their  
629 participants in the USA with an oversampling of Mexican Americans. Research has indicated  
630 that immigration often results in altered dietary behavior often through the inclusion of foods  
631 with high fat and sugar contents and low nutrient density while excluding nutrient-dense foods

632 such as vegetables, fruits, and legumes.<sup>88</sup> Immigration to the USA might have altered  
633 participants' dietary habits to resemble Western dietary patterns with a lower consumption of  
634 legumes and pulses compared to native Mexican citizens still living in Mexico. The results of  
635 the studies including Western Populations<sup>25,41,56,60</sup> indicated that the Westernized population  
636 might not be at increased risk of developing GBD when consuming legumes, and there might  
637 even be an inverse association. Overall, there appears to be a tendency that populations with a  
638 generally greater tradition for consuming legumes and pulses are at greater risk of developing  
639 GBD. Whether the legumes drive this association alone, or it is the combination of foods in  
640 which legumes are consumed is unclear.

#### 641 **Underlying mechanisms**

642 Legumes are well established as a health-promoting dietary factor due to their high contents of  
643 antioxidants, polyphenols, dietary fibers, and bioactive peptides.<sup>8,13,55</sup> Several hepatobiliary  
644 mechanisms have been proposed to be affected by legumes, including digestion, lipid  
645 metabolism, and cholesterol synthesis. Dietary patterns with a high content of legumes have  
646 been associated with a lower risk of NAFLD.<sup>11,12,18,55</sup>

647 Consumption of legumes is linked to lower serum lipids by affecting digestion and bile acid  
648 metabolism.<sup>14-17</sup> Dietary fibers, abundant in legumes, bind cholesterol in the intestine, aiding  
649 its removal from the body. Soluble fibers slow down gastric emptying and nutrient absorption,  
650 reducing the uptake of fats like TG and free fatty acids.<sup>55,89,90</sup> Fibers from legumes also bind  
651 bile acids, reducing their reabsorption into the liver and prompting increased bile acid  
652 production, which in turn lowers hepatic cholesterol levels and serum cholesterol through  
653 negative feedback.<sup>14,89,90</sup> Additionally, bioactive compounds in legumes can lower cholesterol  
654 through lipid metabolism and lipid reabsorption prevention.<sup>89</sup> Simultaneously, resistant  
655 starches from legumes can be fermented by colon bacteria to produce beneficial short-chain  
656 fatty acids like propionate and butyrate. These fatty acids can promote a favorable environment

657 for beneficial colon bacteria, which may affect the lipid metabolism through altered fat  
658 oxidation, lipogenesis, and lipolysis.<sup>55,90</sup>

659 Fat is primarily stored in the liver as TG and individuals with elevated serum levels typically  
660 have an overproduction in the liver combined with impaired TG removal from the blood.<sup>89</sup>  
661 Triglycerides are transported in very low-density lipoproteins (VLDL) and excreted from the  
662 liver into the bloodstream through the intestinal tract.<sup>89</sup> Increased bile acid secretion and  
663 inhibited reabsorption in the intestines can bind TG, facilitating its excretion in feces.<sup>90,91</sup>  
664 These mechanisms lower the availability of circulating lipids that can be stored in the liver  
665 tissue and can thus minimize the risk of NAFLD.

666 Consuming legumes as a diet staple is associated with a high prevalence of gallstones.  
667<sup>15,20,21,64</sup> However, proposed triggers of GBD also include other dietary factors and metabolic  
668 issues, and even some genetic factors have been found to promote the development and  
669 progression of gallstones.<sup>15,19,63,92</sup> NAFLD progression affects bile duct and gallbladder  
670 function by expelling surplus lipid fractions via the gallbladder.<sup>15,19,63</sup> Gallstone formation is a  
671 multifaceted process, with cholesterol supersaturation of bile being a key factor.<sup>15,20,21,61,64</sup> Bile  
672 salts combine with phospholipids and cholesterol to boost cholesterol solubility, but an  
673 imbalance in lipids and bile salts can lead to supersaturation and crystal formation. Elevated  
674 cholesterol levels relative to bile salts and phospholipids lead to cholesterol supersaturation in  
675 bile, fostering crystal precipitation. Increased cholesterol secretion into bile and reduced bile  
676 salt secretion are two metabolic processes contributing to cholesterol supersaturation.<sup>15,20,21,64</sup>  
677 Furthermore, a large proportion of gallstones in Western countries has been related to  
678 metabolic abnormalities linked to overweight and obesity, including NAFLD.<sup>63</sup>

### 679 *Strength and limitations*

680 This scoping review has several strengths including the rigorous literature search strategy. To  
681 our knowledge, the scoping review framework allowed for the inclusion of all literature of

682 relevance to investigate the association between legume consumption and hepatobiliary health.  
683 The review process was extensive including the old nomenclature for NAFLD and the new  
684 nomenclature for MASLD, while evaluating all available data sources not only limited to those  
685 with an evidence level. The methodological assessment of evidence-level articles provided a  
686 tool to critically assess the quality of available research when interpreting the estimated  
687 associations.

688 A scarcity of research in this area led us to broaden the scope of this study, thus including  
689 studies focusing on various aspects of hepatobiliary disorders. The studies were diverse and  
690 heterogeneous, using a wide variety of methods and approaches. The evidence was thus  
691 challenging to synthesize into a clear demonstration of an association between legume  
692 consumption and NAFLD or GBD.

### 693 **Conclusions**

694 Twenty-nine articles investigating the association between consumption of legumes were  
695 included in this review. Seventeen of these investigated NAFLD-outcomes (1 cohort study, 5  
696 case-control studies, 9 cross-sectional studies, 2 reviews) and 12 investigated GBD-outcomes  
697 (2 cohort studies, 5 case-control studies, 2 cross-sectional studies, 3 reviews).

698 Despite some literature indicating a protective association between legumes and NAFLD,  
699 the results were heterogeneous, and a clear association can therefore not be established. The  
700 methodology of the included studies has substantial differences in relation to the assessment of  
701 exposures, and the statistical analyses may have led to diverging results due to different  
702 covariate adjustment strategies. The overall confidence in the evidence varied and more clearly  
703 designed and reported research on the topic is warranted.

704 For gallbladder diseases, the literature was diverging with different magnitudes and  
705 directions of associations rendering a clear conclusion impossible as legume consumption was  
706 reported to be inversely, positively, or not associated with gallbladder diseases.

707 Methodological differences between studies warrant more clearly designed and reported  
708 research. The potential for legume consumption to increase gallstone risk should, however, be  
709 considered in light of the recognized health benefits associated with the consumption of  
710 legumes.

711 Due to the heterogeneity of the results of this review, any proposed underlying mechanisms  
712 between legume consumption and the development of NAFLD or GBD cannot be confirmed.  
713 Future research investigating associations and underlying mechanisms could potentially fill a  
714 substantial knowledge gap and provide important insights into the diet-disease interactions and  
715 underlying pathways.

## 716 **Acknowledgments**

### 717 **Author contributions**

718 FL and CCD were responsible for designing the research question. FL designed the search  
719 strategy with guidance from CCD. FL and CCD drafted the protocol, data extraction template,  
720 and results template, VLM, LR, and NB critically reviewed the protocol and relevant  
721 templates. FL conducted the preliminary search. FL, VLM, CFJ, LR, and NB conducted the  
722 literature screening and full-text review. Data extraction and bias assessment were done by FL,  
723 VLM, CFJ, LR, NB, and CCD. Tabular descriptions of results were done by FL. All authors  
724 critically revised the manuscript and take full responsibility for the content of this scoping  
725 review.

### 726 **Funding**

727 This study was supported by The Graduate School of Health, Aarhus University, Aarhus  
728 Denmark and Department of Public Health, Aarhus University, Aarhus Denmark. The funders  
729 had no role in planning, designing, or conducting the research. The views expressed in this  
730 publication are those of the authors.

731 **Conflict of Interest**

732 The authors declare no conflict of interest.

733 **Data availability**

734 A complete list of all literature identified with the search strategy presented in Appendix I, after  
735 the automatic exclusion of duplicates in Covidence, can be requested from the corresponding  
736 author.

737 **Supporting Information**

738 Appendix I: Search strategy

739 Appendix II: Search strategy for unpublished and grey literature

740 Appendix III: Studies ineligible following full-text review

741 Appendix IV: Data extraction instrument

742 Appendix V: Methodological quality assessment of included studies

743 Appendix VI: Characteristics of included studies

744 Appendix VII: PRISMA-ScR Checklist

745 **References**

- 746 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology  
747 of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and  
748 outcomes. *Hepatology*. 2016;64(1):73-84.
- 749 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic  
750 fatty liver disease: Practice guidance from the American Association for the Study of Liver  
751 Diseases. *Hepatology*. 2018;67(1):328-357.
- 752 3. He K, Li Y, Guo X, Zhong L, Tang S. Food groups and the likelihood of non-alcoholic fatty  
753 liver disease: a systematic review and meta-analysis. *Br J Nutr*. 2020;124(1):1-13.
- 754 4. Food and Agriculture Organization of the United Nations. What are pulses? FAO Available  
755 at: <https://www.fao.org/pulses-2016/news/news-detail/en/c/337107/>. Accessed on November  
756 23, 2022.
- 757 5. Willett W, Rockström J, Loken B, et al. Food in the Anthropocene: the EAT-Lancet  
758 Commission on healthy diets from sustainable food systems. *Lancet*.  
759 2019;393(10170):447-492.
- 760 6. Rebello CJ, Greenway FL, Finley JW. A review of the nutritional value of legumes and their  
761 effects on obesity and its related co-morbidities. *Obes Rev*. 2014;15(5):392-407.
- 762 7. Mudryj AN, Yu N, Hartman TJ, Mitchell DC, Lawrence FR, Aukema HM. Pulse  
763 consumption in Canadian adults influences nutrient intakes. *Br J Nutr*. 2012;108 (Suppl  
764 1):S27-36.
- 765 8. Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple  
766 health outcomes: A systematic review with meta-analysis of observational studies. *Crit Rev*  
767 *Food Sci Nutr* 2017;57(17):3640-3649.
- 768 9. Becerra-Tomás N, Papandreou C, Salas-Salvadó J. Legume Consumption and  
769 Cardiometabolic Health. *Adv Nutr*. 2019;10(6):S437-450.



- 770 10. Miller V, Mente A, Dehghan M, et al. Fruit, vegetable, and legume intake, and  
771 cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. *Lancet*.  
772 2017;390(10107):2037-2049.
- 773 11. Abenavoli L, Di Renzo L, Boccuto L, Alwardat N, Gratteri S, De Lorenzo A. Health  
774 benefits of Mediterranean diet in nonalcoholic fatty liver disease. *Expert Rev Gastroenterol*  
775 *Hepatol*. 2018;12(9):873-881.
- 776 12. Alferink LJM, Erler NS, de Kneegt RJ, et al. Adherence to a plant-based, high-fibre dietary  
777 pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. *Eur*  
778 *J Epidemiol*. 2020;35(11):1069-1085.
- 779 13. Rutherford-Markwick KJ. Food proteins as a source of bioactive peptides with diverse  
780 functions. *Br J Nutr*. 2012;108 (Suppl 2):S149-157.
- 781 14. Li T, Francl JM, Boehme S, Chiang JYL. Regulation of cholesterol and bile acid  
782 homeostasis by the cholesterol 7 $\alpha$ -hydroxylase/steroid response element-binding protein  
783 2/microRNA-33a axis in mice. *Hepatology*. 2013;58(3):1111-1121.
- 784 15. Di Ciaula A, Wang DQ, Garruti G, et al. Therapeutic reflections in cholesterol homeostasis  
785 and gallstone disease: a review. *Curr Med Chem*. 2014;21(12):1435-1447.
- 786 16. Hong J, Kim S, Kim H-S. Hepatoprotective Effects of Soybean Embryo by Enhancing  
787 Adiponectin-Mediated AMP-Activated Protein Kinase  $\alpha$  Pathway in High-Fat and  
788 High-Cholesterol Diet-Induced Nonalcoholic Fatty Liver Disease. *J Med Food*.  
789 2016;19(6):549-559.
- 790 17. Son Y, Jang MK, Jung MH. Vigna nakashimae extract prevents hepatic steatosis in obese  
791 mice fed high-fat diets. *J Med Food*. 2014;17(12):1322-1331.
- 792 18. Lander EM, Wertheim BC, Koch SM, Chen Z, Hsu C-H, Thomson CA. Vegetable protein  
793 intake is associated with lower gallbladder disease risk: Findings from the Women's Health  
794 Initiative prospective cohort. *Prev Med*. 2016;88:20-26.
- 795 19. Li X, Gao P. Fatty liver increases gallstone disease risk in younger Chinese patients.  
796 *Medicine (Baltimore)*. 2019;98(22):e15940.

- 797 20. Nervi F, Covarrubias C, Bravo P, et al. Influence of legume intake on biliary lipids and  
798 cholesterol saturation in young Chilean men. Identification of a dietary risk factor for  
799 cholesterol gallstone formation in a highly prevalent area. *Gastroenterology*.  
800 1989;96(3):825-830.
- 801 21. Gaby AR. Nutritional approaches to prevention and treatment of gallstones. *Altern Med*  
802 *Rev*. 2009;14(3):258-267.
- 803 22. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Dietary protein and the risk of  
804 cholecystectomy in a cohort of US women: the Nurses' Health Study. *Am J Epidemiol*.  
805 2004;160(1):11-18.
- 806 23. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal  
807 adiposity and gallstone disease in US men. *Am J Clin Nutr*. 2004;80(1):38-44.
- 808 24. Ainsworth AP, Adamsen S, Rosenberg J. Cholecystectomy in Denmark 1989-2003.  
809 *Ugeskrift for læger*. 2005;167(24):2648-2650.
- 810 25. Thijs C, Knipschild P. Legume intake and gallstone risk: results from a case-control study.  
811 *Int J Epidemiol*. 1990;19(3):660-663.
- 812 26. World Health Organization. Infant and young child feeding. World Health Organization  
813 Available at:  
814 <https://www.who.int/news-room/fact-sheets/detail/infant-and-young-child-feeding>. Accessed  
815 on July 26, 2024.
- 816 27. Langmann F, Mortensen V, Rosendal L, Bock N, Dahm C. Consumption of legumes and  
817 risk of hepatobiliary diseases among humans aged 2+ years: a scoping review protocol. *Open*  
818 *Science Framework*. 2023:1-22. Available at: <https://doi.org/10.17605/OSF.IO/FTVPQ>.
- 819 28. Gutt C, Schläfer S, Lammert F. The Treatment of Gallstone Disease. *Dtsch Arztebl Int*.  
820 2020;117(9):148-158.
- 821 29. Belbase N, Sagar K, Nishnata K, Bhujel S, Prasad U, Bikash S. To study the indications of  
822 cholecystectomy, types of surgery and complications of surgery in a tertiary care hospital in  
823 Nepal. *Archives of Clinical Gastroenterology*. 2022;8:020-024.

- 824 30. Thornton J. Associations rename fatty liver disease to reduce stigma. *BMJ*. 2023;382:1587.
- 825 31. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic  
826 dysfunction-associated fatty liver disease: An international expert consensus statement. *J*  
827 *Hepatol*. 2020;73(1):202-209.
- 828 32. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews  
829 (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-473.
- 830 33. Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different  
831 nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. *J Hepatol*  
832 2024;80(2):e64-66.
- 833 34. Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in  
834 epidemiology, pathophysiology, diagnosis, and pharmacotherapy. *Chin Med J*.  
835 2020;134(1):8-19.
- 836 35. Schöpfel J, Farace, JD, Frantzen, J. Data from "OpenGrey, System for Information on Grey  
837 Literature in Europe". *The Grey Journal*. 2021:7.
- 838 36. Scottish Intercollegiate Guidelines Network. Checklists. Healthcare Improvement Scotland  
839 Available at: <https://www.sign.ac.uk/what-we-do/methodology/checklists/>. Accessed on April  
840 11, 2024.
- 841 37. Martin JD, Marnie LB, Hywel CW, Rachel SD. Development of a critical appraisal tool to  
842 assess the quality of cross-sectional studies (AXIS). *BMJ open*. 2016;6(12):e011458.
- 843 38. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic  
844 reviews that include randomised or non-randomised studies of healthcare interventions, or  
845 both. *BMJ*. 2017;358:j4008.
- 846 39. Zhang S, Kumari S, Gu Y, et al. Soy Food Intake Is Inversely Associated with Newly  
847 Diagnosed Nonalcoholic Fatty Liver Disease in the TCLSIH Cohort Study. *J Nutr*.  
848 2020;150(12):3280-3287.

- 849 40. Zhang S, Yan Y, Meng G, et al. Protein foods from animal sources and risk of nonalcoholic  
850 fatty liver disease in representative cohorts from North and South China. *J Intern Med*  
851 2023;293(3):340-353.
- 852 41. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Fruit and vegetable consumption  
853 and risk of cholecystectomy in women. *The American journal of medicine*.  
854 2006;119(9):760-767.
- 855 42. Chiu TH, Lin MN, Pan WH, Chen YC, Lin CL. Vegetarian diet, food substitution, and  
856 nonalcoholic fatty liver. *Ci Ji Yi Xue Za Zhi*. 2018;30(2):102-109.
- 857 43. Bahrami A, Teymoori F, Eslamparast T, et al. Legume intake and risk of nonalcoholic fatty  
858 liver disease. *Indian J Gastroenterol*. 2019;38(1):55-60.
- 859 44. Baratta F, Pastori D, Polimeni L, et al. Adherence to Mediterranean Diet and  
860 Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. *Am J Gastroenterol*.  
861 2017;112(12):1832-1839.
- 862 45. Chan R, Wong VW, Chu WC, et al. Diet-Quality Scores and Prevalence of Nonalcoholic  
863 Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy.  
864 *PLoS One*. 2015;10(9):e0139310.
- 865 46. Giraldi L, Miele L, Aleksovska K, et al. Mediterranean diet and the prevention of  
866 non-alcoholic fatty liver disease: results from a case-control study. *Eur Rev Med Pharmacol*  
867 *Sci*. 2020;24(13):7391-7398.
- 868 47. Han JM, Jo AN, Lee SM, et al. Associations between intakes of individual nutrients or  
869 whole food groups and non-alcoholic fatty liver disease among Korean adults. *J Gastroenterol*  
870 *Hepatol*. 2014;29(6):1265-1272.
- 871 48. Hao X, Ma C, Xiang T, Ou L, Zeng Q. Associations Among Methylene Tetrahydrofolate  
872 Reductase rs1801133 C677T Gene Variant, Food Groups, and Non-alcoholic Fatty Liver  
873 Disease Risk in the Chinese Population. *Front Genet*. 2021;12

- 874 49. Tutunchi H, Saghafi-Asl M, Asghari-Jafarabadi M, Ostadrahimi A. Association between  
875 Dietary Patterns and Non-alcoholic Fatty Liver Disease: Results from a Case-Control Study.  
876 *Arch Iran Med* 2021;24(1):35-42.
- 877 50. Bullón-Vela V, Abete I, Tur JA, et al. Influence of lifestyle factors and staple foods from  
878 the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with  
879 metabolic syndrome features. *Nutrition*. 2020;71:110620.
- 880 51. Mirizzi A, Franco I, Leone CM, et al. Effects of Some Food Components on Non-Alcoholic  
881 Fatty Liver Disease Severity: Results from a Cross-Sectional Study. *Nutrients*.  
882 2019;11(11):2744.
- 883 52. Vijay A, Al-Awadi A, Chalmers J, et al. Development of Food Group Tree-Based Analysis  
884 and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a  
885 South Indian Population: A Large Case-Control Study. *Nutrients*. 2022;14(14):2808.
- 886 53. Watzinger C, Nonnenmacher T, Grafetstätter M, et al. Dietary Factors in Relation to Liver  
887 Fat Content: A Cross-sectional Study. *Nutrients*. 2020;12(3):825.
- 888 54. Yabe Y, Kim T, Oh S, et al. Relationships of dietary habits and physical activity status with  
889 non-alcoholic fatty liver disease featuring advanced fibrosis. *International journal of*  
890 *environmental research and public health*. 2021;18(17):8918.
- 891 55. Mega A, Marzi L, Kob M, Piccin A, Floreani A. Food and nutrition in the pathogenesis of  
892 liver damage. *Nutrients*. 2021;13(4):1326.
- 893 56. Barré A, Gusto G, Cadeau C, Carbonnel F, Boutron-Ruault MC. Diet and Risk of  
894 Cholecystectomy: A Prospective Study Based on the French E3N Cohort. *Am J Gastroenterol*.  
895 2017;112(9):1448-1456.
- 896 57. Jayanthi V, Anand L, Ashok L, Srinivasan V. Dietary factors in pathogenesis of gallstone  
897 disease in southern India--a hospital-based case-control study. *Indian J Gastroenterol*.  
898 2005;24(3):97-99.

- 899 58. Rasheed N, Almeshal RA, Almohaimeed WS, et al. Dietary patterns of females with  
900 cholecystolithiasis: A comprehensive study from central region of Saudi Arabia. *Open Access*  
901 *Maced J Med Sci*. 2020;8(B):1193-1198.
- 902 59. Parveen S, Channa NA, Kalhor DM. Incidence and risk factors of gallstone disease at  
903 Larkana, Pakistan. *RAWAL MEDICAL JOURNAL*. 2019;44(3):544-548.
- 904 60. Pastides H, Tzonou A, Trichopoulos D, et al. A case-control study of the relationship  
905 between smoking, diet, and gallbladder disease. *Arch Intern Med*. 1990;150(7):1409-1412.
- 906 61. Tseng M, DeVellis RF, Maurer KR, et al. Food intake patterns and gallbladder disease in  
907 Mexican Americans. *Public Health Nutr*. 2000;3(2):233-243.
- 908 62. Unisa S, Jagannath P, Dhir V, Khandelwal C, Sarangi L, Roy TK. Population-based study  
909 to estimate prevalence and determine risk factors of gallbladder diseases in the rural Gangetic  
910 basin of North India. *HPB*. 2011;13(2):117-125.
- 911 63. Di Ciaula A, Garruti G, Fruhbeck G, et al. The role of diet in the pathogenesis of cholesterol  
912 gallstones. *Curr Med Chem*. 2019;26(19):3620-3638.
- 913 64. Dietary beans: a risk factor for cholesterol gallstones? *Nutrition reviews*.  
914 1989;47(12):369-371.
- 915 65. Park S, Yoo S, Kim J, An H-T, Kang M, Ko J. 14-3-3 $\beta$  and  $\gamma$  differentially regulate  
916 peroxisome proliferator activated receptor  $\gamma$ 2 transactivation and hepatic lipid metabolism.  
917 *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*.  
918 2015;1849(10):1237-1247.
- 919 66. Flint M, Bowles S, Lynn A, Paxman JR. Novel plant-based meat alternatives: future  
920 opportunities and health considerations. *Proc Nutr Soc*. 2023;82(3):370-385.
- 921 67. Mariotti F. Nutritional and health benefits and risks of plant-based substitute foods. *Proc*  
922 *Nutr Soc*. 2023:1-14.
- 923 68. Villaseñor A, Cadmus-Bertram L, Patterson RE. Overview of Nutritional Epidemiology.  
924 In: Coulston AM, Boushey CJ, Ferruzzi MG, Delahanty LM, eds. *Nutrition in the Prevention*  
925 *and Treatment of Disease* 4th ed. San Diego. Academic Press; 2017:145-165.

- 926 69. Thompson FE, Subar AF. Dietary Assessment Methodology. In: Coulston AM, Boushey  
927 CJ, Ferruzzi MG, Delahanty LM, eds. *Nutrition in the Prevention and Treatment of Disease*.  
928 4th ed. San Diego. Academic Press; 2017:5-48.
- 929 70. Willett W, Lenart E. Reproducibility and Validity of Food Frequency Questionnaires. In:  
930 Willett W, ed. *Nutritional Epidemiology*. 3rd ed. New York. Oxford University Press;  
931 2012:96-141.
- 932 71. Park Y, Dodd KW, Kipnis V, et al. Comparison of self-reported dietary intakes from the  
933 Automated Self-Administered 24-h recall, 4-d food records, and food-frequency  
934 questionnaires against recovery biomarkers<sup>1</sup>. *The American Journal of Clinical Nutrition*.  
935 2018;107(1):80-93.
- 936 72. Sam CHY, Skidmore P, Skeaff S, Wall C, Bradbury KE, Parackal S. Relative Validity and  
937 Reproducibility of a Short FoodFrequency Questionnaire to Assess Nutrient Intakesof New  
938 Zealand Adults. *Nutrients*. 2020;12(3):619.
- 939 73. Jenab M, Slimani N, Bictash M, Ferrari P, Bingham SA. Biomarkers in nutritional  
940 epidemiology: applications, needs and new horizons. *Hum Genet*. 2009;125(5):507-525.
- 941 74. Jager KJ, Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Stel VS. Where to look for the  
942 most frequent biases? *Nephrology* 2020;25(6):435-441.
- 943 75. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical  
944 Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in  
945 Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American  
946 Association for the Study of Liver Diseases (AASLD). *Endocrine Practice*.  
947 2022;28(5):528-562.
- 948 76. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the  
949 Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty  
950 Liver Disease: Expert Review. *Gastroenterology*. 2023;165(4):1080-1088.
- 951 77. European Association for the Study of the Liver (EASL), European Association for the  
952 Study of Diabetes (EASD), European Association for the Study of Obesity (EASO).

- 953 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty  
954 liver disease. *J Hepatol.* 2016;64(6):1388-1402.
- 955 78. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography  
956 (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and  
957 fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? *World J*  
958 *Gastroenterol.* 2016;22(32):7236-7251.
- 959 79. National Institute of Diabetes and Digestive and Kidney Diseases. Diagnosis of Gallstones.  
960 National Institute of Health Available at:  
961 <https://www.niddk.nih.gov/health-information/digestive-diseases/gallstones/diagnosis>.  
962 Accessed on March 19, 2024.
- 963 80. Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis  
964 biomarkers in patients with nonalcoholic fatty liver disease. *Aliment Pharmacol Ther.*  
965 2014;40(10):1209-1222.
- 966 81. Hanna KL, Collins PF. Relationship between living alone and food and nutrient intake.  
967 *Nutr Rev.* 2015;73(9):594-611.
- 968 82. Breen F, Coveney J, Pflaum CAH. A literature scoping review of eating practices and food  
969 environments in 1 and 2-person households in the UK, Australia and USA. *Appetite.*  
970 2018;126:43-53.
- 971 83. Dao MC, Thiron S, Messer E, et al. Cultural Influences on the Regulation of Energy Intake  
972 and Obesity: A Qualitative Study Comparing Food Customs and Attitudes to Eating in Adults  
973 from France and the United States. *Nutrients.* 2020;13(1):63.
- 974 84. Barakat C, Konstantinidis T. A Review of the Relationship between Socioeconomic Status  
975 Change and Health. *International journal of environmental research and public health.*  
976 2023;20(13):6249.
- 977 85. Afshin A, Sur PJ, Fay KA, et al. Health effects of dietary risks in 195 countries, 1990-2017:  
978 a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet.*  
979 2019;393(10184):1958-1972.



- 980 86. Figueira N, Curtain F, Beck E, Grafenauer S. Consumer Understanding and Culinary Use  
981 of Legumes in Australia. *Nutrients*. 2019;11(7):1575.
- 982 87. Heer MM, Winham DM. Bean Preferences Vary by Acculturation Level among Latinas  
983 and by Ethnicity with Non-Hispanic White Women. *International journal of environmental  
984 research and public health*. 2020;17(6):2100.
- 985 88. Mbombo-Dweba T, Oguttu JW, Agyepong N, Mbajourgu CA. Factors influencing dietary  
986 choices of immigrants upon resettlement in host countries – A scoping review. *APPL ECOL  
987 ENV RES*. 2018;16:1329-1351.
- 988 89. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with  
989 dyslipidemia: A Clinical Perspective from the National Lipid Association. *J Clin Lipidol*.  
990 2023;17(4):428-451.
- 991 90. Dahm CC, Langmann F, Nannsen AØ, Ibsen DB. Role of dietary fibres in cardiometabolic  
992 diseases. *Curr Opin Clin Nutr Metab Care*. 2024;27(4):355-360.
- 993 91. Alizadeh M, Gharaaghaji R, Gargari BP. The effects of legumes on metabolic features,  
994 insulin resistance and hepatic function tests in women with central obesity: a randomized  
995 controlled trial. *Int J Prev Med*. 2014;5(6):710-720.
- 996 92. Wang DQH, Cohen DE, Carey MC. Biliary lipids and cholesterol gallstone disease. *J Lipid  
997 Res*. 2009;50:S406-411.

998 Table 1. Overview of eligible research study characteristics

| Study design   | Number and characteristics   | Populations included   | Exposure  | Outcomes   |
|--|--|--|---|--|
| Articles focusing on NAFLD <sup>a</sup>              |  |  |   |  |
| Cohort studies <sup>40</sup>                         | 1 study published in 2023. Number of participants: 15,838. China.  | Healthy general population without CVD <sup>b</sup> or cancer.   | Replacing 25g of other foods with legumes.  | NAFLD  |
| Case-control studies <sup>43,46-49</sup>             | 5 studies published in 2014-2021. Number of participants: 210-4091. 2 Iran, 1 Italy, 1 Korea, 1 China.                               | Healthy general population with low consumption of alcohol and without hepatitis B or C, medically induced fatty liver, liver dysfunction, CVD, endocrine disorders, or cancers.   | Legume intake in frequencies, tertiles, g/day, or servings/week.                                      | NAFLD  |
| Cross-sectional studies <sup>39,42,44,45,50-54</sup> | 9 studies published in 2015-2022. Number of participants: 136-24,622. 2 Italy, 2 China, 1 Spain, 1 Taiwan, 1 Germany, 1 Japan, 1 UK. | High CVD-risk individuals and healthy general population with low consumption of alcohol and tobacco, and without hepatitis, medically induced fatty liver, liver dysfunction, CVD, cancer, or endocrine or GI <sup>c</sup> disorders. | Weekly servings of legumes, legume intake (tertiles or g/day), or replacing 7g meat protein with soy. | NAFLD, NAFLD severity, liver fibrosis, or liver stiffness. |
| Systematic   | 1 review published in 2020. Included   | Adult non-pregnant participants with low   | Legume intake.  | NAFLD  |

|   |   |  |   |                  |
|---|---|--|---|------------------|
| reviews <sup>3</sup>                      | 4 articles within the scope of this review (1 case-control, 3 cross-sectional). 1 China.  | alcohol consumption and without hepatitis B or C, HIV <sup>d</sup> , IBD <sup>e</sup> , coeliac disease, or autoimmune hepatitis.                          |   |                  |
| Narrative reviews <sup>55</sup>           | 1 article published in 2021. 1 Italy.   | Mixed populations, healthy adults, and NAFLD patients.   | Legume intake.                                      | NAFLD            |
| Articles focusing on gallbladder diseases |   |  |   |                  |
| Cohort studies <sup>41,56</sup>           | 2 studies published in 2006-2017.<br>Number of participants: 64,052-77,090. 1 France, 1 USA.  | Women from E3N <sup>f</sup> or Nurses' Health Study without cancer, gallstone, or cholecystectomy.   | Legume intake g/day or servings/week.               | Cholecystectomy  |
| Case-control studies <sup>25,57-60</sup>  | 5 studies published in 1990-2020.<br>Number of participants: 200-819. 1 India, 1 Pakistan, 1 Greece, 1 Saudi Arabia, 1 The Netherlands. | Cholecystectomy and gallstone cases matched with healthy controls. Included individuals not pregnant and without cancer, hepatitis, or AIDS <sup>g</sup> . | Daily, weekly, and monthly legume intake.           | Gallstone        |
| Cross-sectional studies <sup>61,62</sup>  | 2 studies published in 2000-2010.<br>Number of participants: 4641-11,392.<br>1 USA, 1 India.  | Mexican Americans and Indians with gallstone matched with healthy adults   | Intake of chickpeas (yes, no) or beans (frequency). | GBD <sup>h</sup> |

|                                       |   |  |                |                                     |
|---------------------------------------|---|--|----------------|-------------------------------------|
| Narrative reviews <sup>21,63,64</sup> | 3 articles published in 1989-2019. 1 Italy, 1 USA, 1 unknown. | Populations consuming large amounts of legumes | Legume intake. | Gallstone, biliary cholesterol, GBD |
|---------------------------------------|---|--|----------------|-------------------------------------|

999 <sup>a</sup>NAFLD, non-alcoholic fatty liver disease. <sup>b</sup>CVD, cardiovascular disease. <sup>c</sup>GI, gastrointestinal. <sup>d</sup>HIV, human immunodeficiency virus. <sup>e</sup>IBD,  
1000 inflammatory bowel disease. <sup>f</sup>E3N, Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale. <sup>g</sup>AIDS, acquired  
1001 immunodeficiency syndrome. <sup>h</sup>GBD, gallbladder disease.

1002 Table 2. Results table for studies investigating legume consumption and NAFLD<sup>a</sup>, including quality assessment rating.

| Author                               | Population  | Exposure   | Outcome | Result <sup>b</sup> | Quality <sup>c</sup> |
|--------------------------------------|---|--|---------|---------------------|----------------------|
| Cohort studies                       |   |  |         |                     |                      |
| Zhang et al. (2023) <sup>40</sup>    | TCLSIH <sup>d</sup> , n=14,541, 59.9% females, median age 35.9 years.<br>GNHS <sup>e</sup> , n=1297, 69.5% females, median age 59.7 years. China. | Replacing 25 g legumes with equal mass of other foods. | NAFLD   | ≤                   | High                 |
| Case-control studies                 |   |  |         |                     |                      |
| Bahrami et al. (2019) <sup>43</sup>  | 196 NAFLD cases, 803 age and sex-matched controls, 51% females, mean age 41.9 years. Iran.  | Weekly servings of legumes.                            | NAFLD   | <                   | High                 |
| Giraldi et al. (2020) <sup>46</sup>  | 371 NAFLD cases, 32.8% female, mean age 59 years. 444 controls, 41.2% female, mean age 45 years. Italy.   | Low or high legume intake.                             | NAFLD   | <                   | Acceptable           |
| Han et al. (2014) <sup>47</sup>      | 169 NAFLD cases, 179 controls, 52.3% females, age 20-69 years. Korea  | Tertiles of bean intake (g/day).                       | NAFLD   | =                   | Acceptable           |
| Hao et al. (2021) <sup>48</sup>      | 2602 NAFLD cases, 1447 genotype-matched controls, 69-71% females, mean age for cases: 53 years, controls: 53.1 years. China.                      | Weekly consumption frequency of beans.                 | NAFLD   | <                   | Unacceptable         |
| Tutunchi et al. (2021) <sup>49</sup> | 105 NAFLD cases, 105 age and sex-matched controls, 57.2% females, mean for age cases: 45.6 years, controls: 45.4 years. Iran.                     | Tertiles of legume intake (g/day).                     | NAFLD   | =                   | Unacceptable         |
| Cross-sectional studies              |   |  |         |                     |                      |

|   |   |   |                          |   |          |
|---|---|---|--------------------------|---|----------|
| Baratta et al. (2017) <sup>44</sup>     | 584 patients with cardiovascular risk factors, 38.2% females, mean age 56.2 years. Italy.   | Weekly servings of legumes <2 or ≥ 2.                                 | NAFLD                    | = | Low      |
| Bullón-Vela et al. (2019) <sup>50</sup> | 328 individuals with MetS <sup>f</sup> , 45.1% females, mean age 65.8 years. Spain.   | Tertiles of legume intake (g/day).                                    | NAFLD                    | < | Moderate |
| Chan et al. (2015) <sup>45</sup>        | 797 adults, 58.3% females, mean age 48.1 years. China.  | Tertiles of soy food intake (g/day).                                  | NAFLD                    | = | Very low |
| Chiu et al. (2018) <sup>42</sup>        | 4625 participants from the Tzu Chi Health Study. Vegetarian: mean age 54 years, 59% females. Non-vegetarian: mean age 55 years, 78% females. Taiwan.                  | Replacing 7g legume protein with equal mass protein from other foods. | NAFLD                    | = | Low      |
| Mirizzi et al. (2019) <sup>51</sup>     | 136 individuals from NUTRIATT-RCT <sup>g</sup> , 42% females, mean age 49.6 years. Italy.   | Legume intake (g/day).  | NAFLD                    | ≤ | Moderate |
| Vijay et al. (2022) <sup>52</sup>       | 993 NAFLD cases and 973 controls, from the Trivandrum NAFLD cohort, cases: 54.4%, female, mean age 48.16 years, controls: 67.5% females, mean age 45.90 years. India. | Legume intake (g/kg/day).   | Degree of liver fibrosis | < | Moderate |
| Watzinger et                            | 136 overweight individuals from the HELENA trial, without   | Legume intake (g/day).  | NAFLD                    | = | Moderate |

|                                   |   |  |                |   |          |
|-----------------------------------|---|--|----------------|---|----------|
| al. (2020) <sup>53</sup>          | NAFLD: 57.8 %, females, mean age 49.8 years, with NAFLD: 44.4% females, mean age 50.1 years. Germany.   |  |                |   |          |
| Yabe et al. (2021) <sup>54</sup>  | 248 with NAFLD, 52.4% females, mean age 55.8 years. 101 without NAFLD, 71.3% females, mean age 58.4 years. Japan.   | Weekly frequency of soy and soybean intake.    | Liver fibrosis | < | Low      |
| Zhang et al. (2020) <sup>39</sup> | 24,622 participants from TCLSIH. Without NAFLD: 58.8% females, mean age: 38.4 years. With NAFLD: 27.7% females, mean age: 42.4 years. China.                      | Weekly frequency of soy and soybean intake.    | NAFLD          | ≤ | High     |
| Systematic review                 |   |  |                |   |          |
| He et al. (2020) <sup>3</sup>     | Of 24 included studies, four investigated legume intake and NAFLD. Inclusion: Adults, observational studies investigating food groups and validly assessed NAFLD. | Food groups - legumes composed one food group. | NAFLD          | ≤ | Moderate |

1003 <sup>a</sup>NAFLD, non-alcoholic fatty liver disease. <sup>b</sup>Results are presented as “<” corresponding to an inverse association, “≤” corresponding to an inverse  
 1004 or no association, and “=” corresponding to no association. <sup>c</sup>Quality refers to the methodological quality assessment of the study. <sup>d</sup>TCLSIH, Tianjin  
 1005 Chronic Low-grade Systemic Inflammation and Health Cohort. <sup>e</sup>GNHS, Guangzhou Nutrition and Health Study. <sup>f</sup>MetS, metabolic syndrome.  
 1006 <sup>g</sup>NUTRIATT-RCT, Nutrition and Activity Randomized Controlled Trial.

1007 Table 3. Results table for studies investigating legume consumption and gallbladder disease, including quality assessment rating.

| Author                               | Population  | Exposure  | Outcome                       | Result <sup>a</sup> | Quality <sup>b</sup> |
|--------------------------------------|---|---|-------------------------------|---------------------|----------------------|
| Cohort studies                       |   |   |                               |                     |                      |
| Barré et al. (2017) <sup>56</sup>    | 64,052 women from the E3N <sup>c</sup> cohort, mean age 53.7 years for those reporting the outcome, 52.6 years for those not reporting the outcome. France. | Legume intake (g/day)                                   | Self-reported cholecystectomy | <                   | High                 |
| Tsai et al. (2006) <sup>41</sup>     | 77,090 females from Nurses' Health Study, mean age range 47.7-51.7 years across quintiles of legume intake. USA.  | Legume quintiles as weekly servings ranging <0.5 to >2. | Self-reported cholecystectomy | =                   | Acceptable           |
| Case-control studies                 |   |   |                               |                     |                      |
| Jayanthi et al. (2005) <sup>57</sup> | 346 cases and 346 sex and age-matched controls, 51.4% females, mean age cases: 51 years, controls: 50.3 years. India.                                       | Consumption frequency of Tamarind bean paste            | Gallstone                     | >                   | Unacceptable         |
| Parveen et al. (2019) <sup>59</sup>  | 100 cases and 100 sex and age-matched controls, 74% female cases, 44% female controls, mean age not presented. Pakistan.                                    | Weekly legume intake                                    | Gallstone                     | ≥                   | Unacceptable         |
| Pastides et al.                      | 84 gallstone cases, 171 controls, 100% females, mean age  | Monthly legume intake                                   | Gallstone                     | =                   | Unacceptable         |



|  |   |                                   |                                   |   |              |
|--|---|-----------------------------------|-----------------------------------|---|--------------|
| (1990) <sup>60</sup>                   | cases: 54.8 years, controls: 54.3 years. Greece.  | frequency                         |                                   |   |              |
| Rasheed et al.<br>(2020) <sup>58</sup> | 157 gallstone cases, 175 healthy controls, 100% females, mean age not presented. Saudi Arabia.                            | Legume intake                     | Gallstone                         | > | Unacceptable |
| Thijs et al.<br>(1990) <sup>25</sup>   | 204 gallstone cases and 615 controls, 67.7% female cases, 69.4% female controls, mean age not presented. The Netherlands. | Legume intake<br>frequency        | Gallstone                         | < | Unacceptable |
| Cross-sectional studies                |   |                                   |                                   |   |              |
| Tseng et al.<br>(2000) <sup>61</sup>   | 4641 Mexican American participants from NHANES III, 49.7% females, mean age women: 37.5 years, men: 35.8 years. USA.      | Weekly legume intake<br>frequency | Gallstone and<br>cholecystectomy  | ≥ | Low          |
| Unisa et al.<br>(2010) <sup>62</sup>   | 6548 participants, symptomatic patients, 59.9% females, mean age not presented. India.                                    | Chickpea intake<br>(Yes/No)       | GBD <sup>d</sup> and<br>gallstone | ≥ | Very low     |

1008 <sup>a</sup>Results are presented as “<” corresponding to an inverse association, “=” corresponding to no association, “≥” corresponding to a positive or no  
1009 association, and “>” corresponding to a positive association. <sup>b</sup>Quality refers to the methodological quality assessment of the study. <sup>c</sup>E3N, Etude  
1010 Épidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale. <sup>d</sup>GBD, gallbladder disease




Figure 1: Search results, study selection and inclusion process following the PRISMA Extension for Scoping Reviews<sup>32</sup>